Latest Insulin therapy Stories

RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 24, 2012 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present data for three molecules, including two investigational compounds, from their Diabetes Alliance portfolio at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, 1-5 October 2012. Now in its second year, the Boehringer Ingelheim and Lilly Diabetes Alliance continues its commitment to address patient needs...

MILWAUKEE and MADISON, Wis., Sept. 19, 2012 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that it is now accepting applications for Novo Nordisk Community Care Madison/Milwaukee, a community-based initiative that supports local programs that educate people living with type 2 diabetes. The sponsorships are part of the Novo Nordisk Community Care program, which aims to promote sustainable change by working with locally based non-profit groups in...

DANBURY, Conn., Sept. 13, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123. "We are pleased to achieve another milestone in the development of BIOD-123. We continue to meet our timelines and project that we will be able to communicate top-line Phase 2 safety and efficacy data in the third calendar quarter of 2013,"...

KALAMAZOO, Mich., Aug. 29, 2012 /PRNewswire/ -- Researchers at Metabolic Solutions Development Company, LLC (MSDC) have identified a mitochondrial protein complex through which insulin sensitizers achieve their anti-diabetic effects. Findings from this research are being presented August 30 at the Benzon Symposium No. 58 in Copenhagen, Denmark. The newly identified mitochondrial target is being referred to as the mitochondrial Target of Thiazolidinediones, or mTOT((TM)). Key...

RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 17, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta® (linagliptin) tablets for use as add-on therapy to insulin. TRADJENTA is a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes, and can be used as...

Connie K. Ho for redOrbit.com – Your Universe Online Researchers recently discovered that a tuberculosis vaccine could decrease autoimmunity and boost insulin production in patients who have long-term Type 1 diabetes. The vaccine has been utilized for the past 90 years and scientists believe that it could help eliminate the necessity of having insulin injections for patients with Type 1 diabetes. With Type 1 diabetes, patients normally need to inject insulin on a daily basis so...

UCSF study suggests stress-amplifying 'TXNIP' protein may be powerful new drug target At its most fundamental level, diabetes is a disease characterized by stress -- microscopic stress that causes inflammation and the loss of insulin production in the pancreas, and system-wide stress due to the loss of that blood-sugar-regulating hormone. Now, researchers led by scientists at the University of California, San Francisco (UCSF) have uncovered a new key player in amplifying this stress in...

DANBURY, Conn., July 26, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH) has awarded Biodel a grant for the development of concentrated ultra-rapid-acting insulin formulations for use in an artificial pancreas, also known as a closed loop pump system. "We are gratified to receive this award recognizing our innovations in the development of novel therapies to treat...

Newer technologies designed to help people with type 1 diabetes monitor their blood sugar levels daily work better than traditional methods and require fewer painful needle sticks, new Johns Hopkins research suggests. The research findings, published online in the July 10 issue of the Annals of Internal Medicine, suggest that even though these diabetic control technologies are more costly, people with diabetes who use an insulin pump are more satisfied with their treatment and quality of...

Connie K. Ho for redOrbit.com – Your Universe Online Diabetes is a detrimental disease. In order to combat the illness, University of British Columbia (UBC) researchers conducted a study with an industry partner and discovered that stem cells can reverse Type 1 diabetes in mice. The discovery leads the way for the development of innovative treatments of diabetes, which is caused by deficient production of insulin by the pancreas. Insulin allows glucose to be held by the body’s...